Background Richostatin A (TSA) is a nonisoform selective HDAC inhibitor, which can regulate gene expression through modulation of the status of acetylation of histone and non-histone, thus affecting cell proliferation, apoptosis and sensitivity to chemotherapy.TSA combined with erlotinib may enhance the anti-tumor effect of drugs on lung cancer cells.